• Revenue of $3,728 million grew 5.3 percent year-over-year on a reported basis and 5.5 percent at constant currency
• GAAP Net Income of $297 million grew 16.0 percent year-over-year
• Adjusted EBITDA of $864 million grew 8.0 percent year-over-year
• GAAP Diluted Earnings per Share of $1.59 grew 18.7 percent year-over-year
• Adjusted Diluted Earnings per Share of $2.43 declined 0.4 percent year-over-year
• R&D Solutions quarterly bookings of $2.7 billion, representing book-to-bill ratio of 1.28x
• R&D Solutions contracted backlog of $28.4 billion grew 11 percent year-over-year

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2023.

Second-Quarter 2023 Operating Results

Revenue for the second quarter of $3,728 million increased 5.3 percent on a reported basis and 5.5 percent at constant currency, compared to the second quarter of 2022. Technology & Analytics Solutions (TAS) revenue of $1,456 million grew 3.4 percent on a reported basis and 3.4 percent at constant currency. Research & Development Solutions (R&DS) revenue of $2,096 million grew 7.5 percent on a reported basis and 7.6 percent at constant currency. Excluding the impact of pass throughs, R&DS revenue grew 10.2 percent on a reported basis. Contract Sales & Medical Solutions (CSMS) revenue of $176 million decreased 3.8 percent on a reported basis and was flat at constant currency.

As of June 30, 2023, R&DS contracted backlog, including reimbursed expenses, was $28.4 billion, growing 11.1 percent year-over-year and 10.8 percent at constant currency. The company expects approximately $7.3 billion of this backlog to convert to revenue in the next twelve months. The second-quarter book-to-bill ratio was 1.28x. For the twelve months ended June 30, 2023, the book-to-bill ratio was 1.34x.

"IQVIA continues to execute well in a challenging macro environment, delivering another quarter of strong operational and financial results," said Ari Bousbib, chairman and CEO of IQVIA. "Clients on the commercial side remain cautious and spending has not accelerated yet. The clinical business is resilient and performing consistently with our expectations. Industry fundamentals are strong, as reflected in our $2.7 billion of bookings in the quarter and new record highs for RFP flow and backlog."

Second-quarter GAAP Net Income was $297 million and GAAP Diluted Earnings per Share was $1.59. Adjusted Net Income was $454 million and Adjusted Diluted Earnings per Share was $2.43. Adjusted EBITDA was $864 million.

First-Half 2023 Operating Results

Revenue for the first six months of 2023 was $7,380 million, up 3.8 percent on a reported basis and 5.1 percent at constant currency compared to the first six months of 2022. TAS revenue was $2,900 million, representing growth of 1.9 percent on a reported basis and 3.2 percent at constant currency. R&DS revenue was $4,122 million, up 6.1 percent on a reported basis and 7.1 percent at constant currency. CSMS revenue was $358 million, down 5.3 percent on a reported basis and 0.5 percent at constant currency.

GAAP Net Income was $586 million and GAAP Diluted Earnings per Share was $3.12. Adjusted Net Income was $916 million and Adjusted Diluted Earnings per Share was $4.88. Adjusted EBITDA was $1,715 million.

Financial Position

As of June 30, 2023, cash and cash equivalents were $1,382 million and debt was $13,777 million, resulting in net debt of $12,395 million. IQVIA’s Net Leverage Ratio was 3.59x trailing twelve-month Adjusted EBITDA. For the second quarter, Operating Cash Flow was $402 million and Free Cash Flow was $242 million.

Share Repurchase

During the second quarter of 2023, the company repurchased $490 million of its common stock, bringing year-to-date share repurchase activity to $619 million. IQVIA had $736 million of share repurchase authorization remaining as of June 30, 2023. On July 31, 2023, the IQVIA board of directors increased the share repurchase authorization by $2 billion dollars, bringing the total remaining authorization to $2,736 million.

Full-Year 2023 Guidance

The company has updated its full-year guidance to reflect the expectation that the commercial business growth (at constant currency excluding acquisitions and COVID-related work) for the balance of the year will be consistent with the first half. The updated revenue guidance range of $15,050 million to $15,175 million represents growth of 4.4 to 5.3 percent on a reported basis and 4.1 to 5.0 percent at constant currency. The guidance represents a range of 8 to 9 percent revenue growth at constant currency excluding acquisitions and COVID-related work. This revenue guidance continues to assume about 100 basis points of contribution from acquisitions and approximately $600 million of COVID-related revenue step down versus 2022.

Reflecting the adjustment to revenue guidance, the company is also updating its Adjusted EBITDA guidance range to $3,600 million to $3,635 million, representing growth of 7.6 to 8.6 percent, and its Adjusted Diluted Earnings per Share guidance range to $10.20 to $10.45, up 0.4 to 2.9 percent on a reported basis. This Adjusted Diluted Earnings per Share guidance includes the year-over-year impact of the step-up in interest rates and the increase in the UK corporate tax rate. The combined impact of these two non-operational items on the year-over-year growth rate is now approximately 12 percentage points. Excluding these items, Adjusted Diluted Earnings per Share is expected to grow 12 to 15 percent.

Third-Quarter 2023 Guidance

For the third quarter of 2023, the company expects revenue to be between $3,760 million and $3,810 million, representing growth of 5.6 to 7.0 percent on a reported basis and 3.9 to 5.3 percent at constant currency. The company expects Adjusted EBITDA to be between $880 million and $895 million, representing growth of 8.1 to 10.0 percent and Adjusted Diluted Earnings per Share to be between $2.39 and $2.49, representing a decline of 3.6 to growth of 0.4 percent on a reported basis. Excluding the step-up in interest rates and the increase in UK corporate tax rate, Adjusted Diluted Earnings per Share is expected to grow 11 to 15 percent.

All financial guidance assumes foreign currency exchange rates as of July 31, 2023 remain in effect for the forecast period.

Webcast & Conference Call Details

IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its second-quarter 2023 results and its third-quarter and full-year 2023 guidance. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants connect to the call using the information provided in the confirmation email and will be placed directly into the call.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behavior and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our third-quarter and full-year 2023 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, and international conflicts or other disruptions outside of our control such as the current situation in Ukraine and Russia; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or future changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; government regulators or our customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions, inflation, and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to our business, see the “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Note on Non-GAAP Financial Measures

This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted Earnings per Share, Gross Leverage Ratio, Net Leverage Ratio and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, the Company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements, trademarks and trade names from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income attributable to IQVIA Holdings Inc. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. Our third-quarter and full-year 2023 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. For the same reasons, the company is unable to address the probable significance of the unavailable information. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based compensation and other items not reflective of the company's ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP.

IQVIAFIN

View source version on businesswire.com: https://www.businesswire.com/news/home/20230801108351/en/